Group-Based Trajectory Models to Evaluate the Association of Lipid Testing and Statin Adherence.

IF 1.9 Q3 PHARMACOLOGY & PHARMACY
Yun-Yi Pan, Sandeep Devabhakthuni, Catherine E Cooke, Julia F Slejko
{"title":"Group-Based Trajectory Models to Evaluate the Association of Lipid Testing and Statin Adherence.","authors":"Yun-Yi Pan, Sandeep Devabhakthuni, Catherine E Cooke, Julia F Slejko","doi":"10.1007/s40801-024-00472-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Performing lipid testing after statin initiation is recommended to monitor response. Inadequate response may indicate non-adherence, which is associated with an increased risk of cardiovascular events and increased costs. Group-based trajectory modeling is an approach to establish probabilistic developmental trajectories of adherence, differentiating individuals by their distinct longitudinal medication-taking behaviors. We examined whether lipid testing is associated with distinct trajectories of statin adherence among individuals enrolled in a Medicare fee-for-service plan in the USA.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the Centers for Medicare & Medicaid Chronic Condition Warehouse 5% sample of Medicare fee-for-service data between 2006 and 2015. Statin use and lipid testing were identified using claims data. The proportion of days covered was calculated for each 30 days after the index date, which was used to estimate the probability of belonging to each potential adherence trajectory.</p><p><strong>Results: </strong>In a cohort of 138,101 statin initiators, four statin adherence trajectory groups were identified. The four groups were differentiated as \"rapid decline\" (21.53%), \"gradual decline\" (10.25%), \"decline first then improve later\" (26.47%), and \"high adherence\" (41.75%). Compared with \"high adherence,\" initiators who had lipid tests within 360 days after statin initiation were less likely to fall into \"rapid decline\" (adjusted odds ratio: 0.661; 95% confidence interval 0.641-0.683), \"gradual decline\" (adjusted odds ratio: 0.834; 95% confidence interval 0.801-0.868), and \"decline first then improve later\" groups (adjusted odds ratio: 0.936; 95% confidence interval 0.910-0.962).</p><p><strong>Conclusions: </strong>Lipid testing is positively associated with greater use of statin medication across different adherence trajectories in the present study.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs - Real World Outcomes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40801-024-00472-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Performing lipid testing after statin initiation is recommended to monitor response. Inadequate response may indicate non-adherence, which is associated with an increased risk of cardiovascular events and increased costs. Group-based trajectory modeling is an approach to establish probabilistic developmental trajectories of adherence, differentiating individuals by their distinct longitudinal medication-taking behaviors. We examined whether lipid testing is associated with distinct trajectories of statin adherence among individuals enrolled in a Medicare fee-for-service plan in the USA.

Methods: A retrospective cohort study was conducted using the Centers for Medicare & Medicaid Chronic Condition Warehouse 5% sample of Medicare fee-for-service data between 2006 and 2015. Statin use and lipid testing were identified using claims data. The proportion of days covered was calculated for each 30 days after the index date, which was used to estimate the probability of belonging to each potential adherence trajectory.

Results: In a cohort of 138,101 statin initiators, four statin adherence trajectory groups were identified. The four groups were differentiated as "rapid decline" (21.53%), "gradual decline" (10.25%), "decline first then improve later" (26.47%), and "high adherence" (41.75%). Compared with "high adherence," initiators who had lipid tests within 360 days after statin initiation were less likely to fall into "rapid decline" (adjusted odds ratio: 0.661; 95% confidence interval 0.641-0.683), "gradual decline" (adjusted odds ratio: 0.834; 95% confidence interval 0.801-0.868), and "decline first then improve later" groups (adjusted odds ratio: 0.936; 95% confidence interval 0.910-0.962).

Conclusions: Lipid testing is positively associated with greater use of statin medication across different adherence trajectories in the present study.

基于组的轨迹模型评估脂质检测与他汀类药物依从性的关系。
背景和目的:建议在他汀类药物开始治疗后进行脂质检测以监测反应。反应不足可能表明未依从性,这与心血管事件风险增加和费用增加有关。基于群体的轨迹建模是一种建立依从性概率发展轨迹的方法,通过个体不同的纵向服药行为来区分个体。我们研究了脂质测试是否与参加美国医疗保险服务收费计划的个体的他汀类药物依从性的不同轨迹有关。方法:采用美国联邦医疗保险和医疗补助慢性病中心2006年至2015年5%的医疗保险按服务收费数据样本进行回顾性队列研究。他汀类药物的使用和脂质测试是根据索赔数据确定的。指标日期后每30天计算覆盖天数的比例,用于估计属于每种潜在坚持轨迹的概率。结果:在138,101名他汀类药物起始者的队列中,确定了四个他汀类药物依从性轨迹组。四组分别为“快速下降”(21.53%)、“逐渐下降”(10.25%)、“先下降后好转”(26.47%)和“高依从性”(41.75%)。与“高依从性”相比,在他汀类药物开始治疗后360天内进行脂质测试的起始者不太可能陷入“快速下降”(调整优势比:0.661;95%可信区间0.641-0.683),“逐渐下降”(调整后优势比:0.834;95%可信区间0.801-0.868),“先下降后提高”组(调整后优势比:0.936;95%置信区间0.910-0.962)。结论:在本研究中,脂质检测与不同依从性的他汀类药物的更多使用呈正相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drugs - Real World Outcomes
Drugs - Real World Outcomes PHARMACOLOGY & PHARMACY-
CiteScore
3.60
自引率
5.00%
发文量
49
审稿时长
8 weeks
期刊介绍: Drugs - Real World Outcomes targets original research and definitive reviews regarding the use of real-world data to evaluate health outcomes and inform healthcare decision-making on drugs, devices and other interventions in clinical practice. The journal includes, but is not limited to, the following research areas: Using registries/databases/health records and other non-selected observational datasets to investigate: drug use and treatment outcomes prescription patterns drug safety signals adherence to treatment guidelines benefit : risk profiles comparative effectiveness economic analyses including cost-of-illness Data-driven research methodologies, including the capture, curation, search, sharing, analysis and interpretation of ‘big data’ Techniques and approaches to optimise real-world modelling.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信